Amgen reported compelling new data from a clinical trial demonstrating its cholesterol-lowering injection Repatha’s ability to reduce the risk of a composite endpoint including heart disease death, heart attacks, and strokes in a primary prevention population of 12,000 patients. The positive results, highlighted by STAT, bolster the potential for broader adoption of PCSK9 inhibitors after previous slow uptake. The trial's success has driven up Amgen’s sales, with Repatha generating $2.2 billion globally in 2024, a 22% year-over-year increase. Analysts suggest significant market upside as many patients still fail to meet LDL cholesterol targets despite available therapies.